Quick Answer
Seres Therapeutics, Inc. reported Net Income of $5.70 million for fiscal year 2025.
Seres Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $5.70M | +4088.2% |
| 2024 | $136.0K | +100.1% |
| 2023 | -$113.72M | +54.5% |
| 2022 | -$250.16M | -281.5% |
| 2021 | -$65.58M | +26.4% |
| 2020 | -$89.13M | -26.8% |
| 2019 | -$70.28M | +29.0% |
| 2018 | -$98.94M | -10.7% |
| 2017 | -$89.38M | +2.4% |
| 2016 | -$91.58M | -67.2% |
| 2015 | -$54.78M | -227.8% |
| 2014 | -$16.71M | -173.8% |
| 2013 | -$6.10M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.20M | -90.8% | +141.3% |
| June 30, 2025 | -$19.86M | +39.6% | -160.8% |
| March 31, 2025 | $32.68M | +181.4% | -63.2% |
| September 30, 2024 | $88.78M | +285.5% | +370.1% |
| June 30, 2024 | -$32.87M | -170.6% | +18.1% |
| March 31, 2024 | -$40.13M | +43.6% | +16.1% |
| September 30, 2023 | -$47.85M | +20.2% | -202.8% |
| June 30, 2023 | $46.55M | +171.9% | +165.4% |
- Seres Therapeutics, Inc. showed an increase of +4088.2% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Seres Therapeutics, Inc.’s net income has grown by 193.3% (from -$6.10 million to $5.70 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: